Citations

Clear

88 citation(s) found for "Ferrer, A".

Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis
Mudappathi, Rekha , Finke, Christy M. , Gangat, Naseema , Abraham, Roshini S. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Ferrer, Alejandro , Lasho, Terra L. , Carr, Ryan M , Fernandez, Jenna , Binder, Moritz , Wang, Junwen

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8672-8673

10.1182/blood-2022-167808 Get It

TELOMERE LENGTH OF PERIPHERAL BLOOD MONONUCLEAR CELLS IS ASSOCIATED WITH DISCHARGE DISPOSITION IN OLDER TRAUMA PATIENTS
Goswami, Julie , Ramachandran, Dhanya , Mahony, C , Howick, Annelise S, Price-Troska, Tammy, Thompson, Riley J., Spears, Grant M. , Bailey, Kent R. , Patnaik, Mrinal S., Passos, João F. , Park, Myung S., MacArthur, Taleen A. , Mahony, Cillian R, Passos, João F , Patnaik, Mrinal S., Ferrer, Alejandro

Mayo Clinic

Shock | November 25, 2022 | Volume: 59 | Issue: 3 | Pages: 327-333

10.1097/shk.0000000000002059 | PMID 36427074 Get It

ABSTRACT Introduction: Little is known regarding peripheral blood mononuclear cell telomere length (PBMC-TL) and response to traumatic injury. The objective of this study was to characterize the role of PBMC-TL in coagulation and clinical outcomes after injury. Methods: Plasma and buffy coats were prospectively collected from trauma patients and healthy volunteers. DNA was purified and PBMC-TL quantified by quantitative polymerase chain reaction. Thrombin generation kinetics were expressed as lag time (in minutes), peak height (in nanometers), time to peak (in minutes), and endogenous thrombin potential (in nM × min). Results are in median and quartiles [Q1, Q3]. P < 0.05 was considered significant (Wilcoxon rank sum testing). Results: Forty-two younger patients (21 [20, 22] years, 69% were male) and 39 older patients (62 [61, 64] years, 79% were male) were included. There was no significant difference in Clinical Frailty Scores between groups. Younger patients had longer total PBMC-TL (0.40 Mb [0.30, 0.49] vs. 0.29 Mb [0.23, 0.33], P < 0.001) and longer average PBMC-TL per chromosome (4.3 kb [3.3, 5.3] vs. 3.2 kb [2.5, 3.7], P < 0.001). When older patients were stratified by 50th percentile of PBMC-TL, there were no differences in thrombin generation; however, those with shorter telomeres were less likely to be discharged home (29% vs. 77%, P = 0.004). Older patients in the bottom quartile of PBMC-TL had shorter lag time (2.78 min [2.33, 3.00] vs. 3.33 min [3.24, 3.89], P = 0.030) and were less likely to be discharged home (22% vs. 90%, P = 0.006) than those in the top quartile of PBMC-TL. Multivariable logistic regression models revealed both increased age and shorter PBMC-TL to be independent predictors of discharge disposition other than home. Conclusion: In older trauma patients, shorter PBMC-TL is associated with accelerated initiation of thrombin generation and lower likelihood of being discharged to home.
Early expression of mature αβ TCR in CD4 − CD8 − T cell progenitors enables MHC to drive development of T-ALL bearing NOTCH mutations
Laffey, Kimberly G. , Stiles, Robert J. , Ludescher, Melissa, Davis, Tessa R. , Khwaja, Shariq S., Bram, Richard J. , Wettstein, Peter J., Ramachandran, Venkataraman , Parks, Christopher A. , Reyes, Edwin E. , Canfield, Jenna M. , Johnson, Cory , Gil, Diana , Schrum, Adam G. , Ludescher, Melissa J, Canfield, Jenna M , Schrum, Adam G , Ferrer, Alejandro , Hammer, Richard

Mayo Clinic

Proceedings of the National Academy of Sciences | June 29, 2022 | Volume: 119 | Issue: 27 | Pages: No page available

10.1073/pnas.2118529119 | PMID 35767640 Get It

During normal T cell development in mouse and human, a low-frequency population of immature CD4 − CD8 − double-negative (DN) thymocytes expresses early, mature αβ T cell antigen receptor (TCR). We report that these early αβ TCR+ DN (EADN) cells are DN3b-DN4 stage and require CD3δ but not major histocompatibility complex (MHC) for their generation/detection. When MHC - is present, however, EADN cells can respond to it, displaying a degree of coreceptor-independent MHC reactivity not typical of mature, conventional αβ T cells. We found these data to be connected with observations that EADN cells were susceptible to T cell acute lymphoblastic leukemia (T-ALL) transformation in both humans and mice. Using the OT-1 TCR transgenic system to model EADN-stage αβ TCR expression, we found that EADN leukemogenesis required MHC to induce development of T-ALL bearing NOTCH1 mutations. This leukemia-driving MHC requirement could be lost, however, upon passaging the tumors in vivo, even when matching MHC was continuously present in recipient animals and on the tumor cells themselves. These data demonstrate that MHC:TCR signaling can be required to initiate a cancer phenotype from an understudied developmental state that appears to be represented in the mouse and human disease spectrum.
P730: GENETIC LANDSCAPE OF SOMATIC MYELOID MUTATIONS IN THE PRESENCE OF RARE TERT VARIANTS AND THEIR RELATION WITH MYELOID NEOPLASIA
Mangaonkar, A., Lasho, T., Wylam, Mark E. , Finke, C., Fernández, José Parejo, He, Rong , Viswanatha, David S., Patnaik, M., Ferrer, Alejandro , Lasho, Terra L. , Finke, Christy M. , Fernandez, J.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 625-626

10.1097/01.hs9.0000845804.52338.42 Get It

Heterozygous variants in PRPF8 are associated with neurodevelopmental disorders
O’Grady, Lauren , Vergano, Samantha A. Schrier , Hoffman, Trevor L. , Sarco, Dean, Cherny, Sara , Bryant, Emily , Schultz‐Rogers, Laura , Sacharow, Stephanie , Immken, LaDonna, Holder, Susan, Blackwell, Rebecca R., Buchanan, Catherine A., Yusupov, Roman, Lecoquierre, François , Guerrot, Anne‐Marie , Rodan, Lance H. , Vries, Bert B.A. de , Kamsteeg, Erik Jan, Palomares‐Bralo, María , Brown, Natasha J. , Klee, Eric W. , Babovic‐Vuksanovic, Dusica , Rhodes, Lindsay, Person, Richard, Begtrup, Amber, Keller‐Ramey, Jennifer, Santiago‐Sim, Teresa, Schnur, Rhonda E. , Gold, Nina B. , Schrier Vergano, Samantha , Lecoquierre, Francois , Rodan, Lance , de Vries, Bert B A , Santos Simarro, Fernando , Palomares-Bralo, Maria , Babovic-Vuksanovic, Dusica, Sweetser, David A , Chung, Wendy K. , Pais, Lynn , Ferrer, Alejandro , Begtrup, Amber Hogart

Mayo Clinic

American Journal of Medical Genetics Part A | May 11, 2022 | Volume: 188 | Issue: 9 | Pages: 2750-2759

10.1002/ajmg.a.62772 | PMID 35543142 Get It

Abstract The pre‐mRNA‐processing factor 8, encoded by PRPF8, is a scaffolding component of a spliceosome complex involved in the removal of introns from mRNA precursors. Previously, heterozygous pathogenic variants in PRPF8 have been associated with autosomal dominant retinitis pigmentosa. More recently, PRPF8 was suggested as a candidate gene for autism spectrum disorder due to the enrichment of sequence variants in this gene in individuals with neurodevelopmental disorders. We report 14 individuals with various forms of neurodevelopmental conditions, found to have heterozygous, predominantly de novo, missense, and loss‐of‐function variants in PRPF8 . These individuals have clinical features that may represent a new neurodevelopmental syndrome.
Telogator: a method for reporting chromosome-specific telomere lengths from long reads
Stephens, Zachary, Ferrer, Alejandro, Boardman, Lisa, Kocher, Jean‐Pierre , Kocher, Jean-Pierre A , Ferrer, Alejandro , Boardman, Lisa, Iyer, Ravishankar K.

Mayo Clinic

Bioinformatics | January 10, 2022 | Volume: 38 | Issue: 7 | Pages: 1788-1793

10.1093/bioinformatics/btac005 | PMID 35022670 Get It

Abstract Motivation Telomeres are the repetitive sequences found at the ends of eukaryotic chromosomes and are often thought of as a ‘biological clock,’ with their average length shortening during division in most cells. In addition to their association with senescence, abnormal telomere lengths are well known to be associated with multiple cancers, short telomere syndromes and as risk factors for a broad range of diseases. While a majority of methods for measuring telomere length will report average lengths across all chromosomes, it is known that aberrations in specific chromosome arms are biomarkers for certain diseases. Due to their repetitive nature, characterizing telomeres at this resolution is prohibitive for short read sequencing approaches, and is challenging still even with longer reads. Results We present Telogator: a method for reporting chromosome-specific telomere length from long read sequencing data. We demonstrate Telogator’s sensitivity in detecting chromosome-specific telomere length in simulated data across a range of read lengths and error rates. Telogator is then applied to 10 germline samples, yielding a high correlation with short read methods in reporting average telomere length. In addition, we investigate common subtelomere rearrangements and identify the minimum read length required to anchor telomere/subtelomere boundaries in samples with these haplotypes. Availability and implementation Telogator is written in Python3 and is available at github.com/zstephens/telogator. Supplementary information Supplementary data are available at Bioinformatics online.
Waist‐hip ratio as a moderator of the effects of hormone therapy on cognitive function in recently menopausal women
James, Taryn T. , Simó, Carola A. Ferrer, Bouges, Shenikqua , Lambrou, Nickolas H., Hulle, Carol A. Van , Wyman, Mary F. , Salazar, Hector , Umucu, Emre , Cedars, Marcelle I. , Løbo, Rogerio A. , Neal‐Perry, Genevieve , Harman, S. Mitchell , Miller, Virginia M. , Gleason, Carey E. , Dowling, N. Maritza , Zuelsdorff, Megan L. , Johnson, Adrienne L. , Kara, Firat , Manson, JoAnn E. , Brinton, Eliot A. , Santoro, Nanette F. , Naftolin, Frederick , Pal, Lubna , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.056539 Get It

AbstractBackgroundResearch on menopausal hormone therapy (MHT) for the reduction/prevention of cognitive decline or Alzheimer’s disease has been inconsistent. The Women’s Health Initiative Memory Study (WHIMS) revealed elevated incident cognitive impairment for women starting MHT after age >65 with oral conjugated equine estrogens (o‐CEE) treatment, especially among women with diabetes. Subsequently, the Cognitive and Affective substudy of the Kronos Early Estrogen Prevention Study (KEEPS‐Cog) found that MHT initiated soon after menopause caused neither cognitive benefit nor harm. Waist‐to‐hip ratio (WHR) is a measure of central adiposity and a surrogate marker for insulin resistance/prediabetes. To explore effects of MHT in insulin‐resistant states, in younger women, we analyzed WHR as a predictor of cognitive response to MHT in KEEPS‐Cog.MethodsKEEPS‐Cog randomized women less than 36‐months postmenopause to oCEE, transdermal 17‐β‐estradiol (tE2) or placebo for 48 months. Cognitive tests, completed at baseline, 18, 36, and 48 months post‐randomization were summarized as factor scores representing four cognitive domains: verbal learning and memory (VLM), auditory attention and working memory (AAWM), visual attention and executive function (VAEF), and speeded language and mental flexibility (SLMF). WHR, measured at screening and months 12, 36, and 48 was modeled as a time‐varying moderator of MHT on cognitive function over time. Education was included as a time‐invariant covariate.ResultsWHR decreased throughout the study in both the tE2 and oCEE groups compared to placebo. WHR was also inversely associated with all cognitive parameters at baseline. The inverse relationship of WHR on SLMF was significant at baseline and month 18, but decreased at month 48. The inverse relationship of WHR on VLM increased significantly over time. Models including interaction effects were significant for oCEE x WHR effects at months 18, 36, and 48 on SLMF, indicating better performance in MHT vs placebo arms. No other interaction effects were significant.ConclusionsWHR decreased with MHT, and was consistently associated with VLM through 4 years of MHT. Further, women on oCEE performed better on SLMF tasks at a given WHR. Differences between KEEPS‐Cog and WHIMS findings may be related to the timing of MHT administration, and effects on central adiposity/insulin resistance/prediabetes.
Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)
Shao, Xiangqiang , Mani, Coumarane, He, Rong , Danos, Arpad , Sheta, Lana , Terraf, Panieh, Raca, Gordana , Williams, Heather , Blombery, Piers , Viswanatha, David S., Jiang, Nan , Vavra, Kevin C., Zhang, Liying , Li, Yuwen , Zhong, Yiming , Matthew, Mariam T, Deeb, Kristin K. , Zhang, Fengli , Liu, Jie , Zhao, Xiaonan, Kopp, Nathan , Pondugula, Santhi , Fakim, Yasmina Jaufeerally , Wu, David , Pullarkat, Sheeja T. , Kulkarni, Shashikant , Madhavan, Subha , Kanagal‐Shamanna, Rashmi , Xu, Xinjie , Kanagal-Shamanna, Rashmi , Rao, Shruti , Saliba, Jason , Kesserwan, Chimene A. , Eno, Celeste , Jiang, Nan, Shi, Zonggao , Li, Peng , Ouseph, Madhu M. , Thompson, Ella R. , Krysiak, Kilannin , Wagner, Alex H. , McCoy, Matthew , Zhao, Xiaonan, Ferrer, Alejandro , Zhang, Wenying , Griffith, Obi L. , Griffith, Malachi

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 4387-4387

10.1182/blood-2021-153546 Get It

Abstract Clinical significance of somatic gene variants needs to be comprehensively characterized for their diagnostic, prognostic and/or therapeutic actionability in patient management. However, challenges remain due to discrepancies in interpretation and reporting of these somatic variants among different testing labs. Therefore, standardized curation, clinical interpretation and reporting of somatic variants in hematologic cancers is critical. To address this issue, the Hematologic Cancer Taskforce (HCT), composed of 52 multi-disciplinary experts including oncologists, molecular pathologists, lab directors, genomic scientists and biocurators, was formed in January 2020 within the ClinGen Somatic Cancer Clinical Domain Working Group (CDWG) with a goal to undertake systematic curation and evidence-based clinical interpretation of genes/somatic variants associated with hematologic malignancies. In collaboration with the Clinical Interpretation of Variants in Cancer (CIViC) (civicdb.org) knowledgebase, HCT members curate, edit, and verify Evidence Items for each variant extracted from peer-reviewed publications. Monthly discussions based on these Evidence Items lead to the preparation of variant Assertions, which summarize the state of the field consensus variant interpretation and include tiering based on the AMP/ASCO/CAP guidelines (PMID: 27993330). FMS-like tyrosine kinase 3 (FLT3) encodes a class III receptor tyrosine kinase expressed in hematopoietic cells. FLT3 mutations, including both internal tandem duplication (ITD) and mutations in the tyrosine kinase domain (TKD), are the most common mutations in acute myeloid leukemia (AML), occurring in approximately 30% of all AML cases. Implementing FLT3 tyrosine kinase inhibitors (TKIs) in different treatment regimens for FLT3 mutated AML patients has led to significantly improved overall survival. Type I FLT3 inhibitors, including midostaurin, gilteritinib, sunitinib, lestaurtinib, and crenolanib, bind to the ATP-binding site when the receptor is in active conformation. Type II FLT3 inhibitors, including sorafenib, ponatinib, and quizartinib, interact with a hydrophobic region directly adjacent to the ATP-binding domain that is only accessible when the receptor is inactive, which prevents receptor activation. Generally in AML cells, type I FLT3 inhibitors prevent activity for both ITD and TKD mutations, while Type II inhibitors target ITD but lack efficiency against TKD mutations. The development of TKD mutations in AML cells with ITD have proved to be a mechanism of acquired, or secondary resistance to Type II FLT3 inhibitors. The HCT is piloting curation assessments of FLT3 alterations, including ITD, TKD and non-TKD variants, in AML. So far, the HCT has curated 75 evidence items for FLT3 somatic variants. FLT3-ITD, as well as D835 and I836 were asserted as tier 1 level A variants based on the prediction of response to gilteritinib in relapsed/refractory AML (PMIDs: 27993330, 31665578, 28645776, 28516360, 27908881). Recent curation activities are focused on FLT3 D839G and N676K, as clinical trials using large AML patient cohorts are lacking in their ability to validate drug response/resistance associations of these two TKD variants due to their low frequency. Functional studies showed both variants result in increased proliferation and protection from apoptosis, supporting the oncogenic potential of these two variants (PMIDs: 26891877, 2468088). FLT3 D839G combined with ITD confers resistance to pexidartinib and ponatinib, both Type II FLT3 inhibitors (PMIDs: 25847190, 23430109). FLT3 N676K predicts response to the Type I FLT3 inhibitor, gilteritinib, when N676K is present alone or in combination with ITD. Interestingly, FLT3 N676K in the absence of ITD predicts response to sorafenib, a Type II FLT3 inhibitor (PMIDs: 32040554, 32984009). However, these results are mostly derived from in vitro studies. Two separate Tier II, Level D Assertions have been submitted for FLT3-ITD&D839G for its response to pexidartinib and ponatinib, and more evidence is being collected to form an Assertion for FLT3 N676K. The complexity of the prediction of response/resistance associated with FLT3 D839G and N676K supports the importance of evidence-based curation and collection for these variants in the context of the overall mutation profile, disease context and specific FLT3 TKIs to clearly define their clinical impact. Disclosures Pullarkat: Stemline Therapeutics: Honoraria.
Clinicoradiographic and genetic features of cerebral small vessel disease indicate variability in mode of inheritance for monoallelic HTRA1 variants
Muthusamy, Karthik , Klee, Eric W. , Wierenga, Klaas J. , Gavrilova, Ralitza H. , Muthusamy, Karthik , Ferrer, Alejandro

Mayo Clinic

Molecular Genetics & Genomic Medicine | September 12, 2021 | Volume: 9 | Issue: 10 | Pages: No page available

10.1002/mgg3.1799 | PMID 34510819 Get It

AbstractBackgroundBiallelic pathogenic variants in HTRA1 cause CARASIL. More recently, monoallelic variants have been associated with the autosomal dominant disorder CADASIL2 but not all carriers develop disease manifestations. We describe the clinicoradiologic and mutation spectrum of four new CADASIL2 individuals.MethodsMedical records at Mayo Clinic between 2013 and 2020 were retrospectively reviewed to identify patients with cerebral small vessel disease related to monoallelic HTRA1 variants.ResultsFour patients met the study inclusion criteria for cerebral small vessel disease related to HTRA1 monoallelic variants. The mean age at onset of first clinical stroke was 51.25 years (range 41–64 years). The mean disease duration was 6.5 years (range 4–12). All individuals had recurrent strokes within the duration of follow‐up with a mean number of strokes per patient being 5.5 (range 2–12). Three individuals had leukoencephalopathy with brain stem involvement. Microhemorrhages were seen on brain MRI in three patients. HTRA1 monoallelic variants identified in our cohort were missense variants in three patients and a novel frameshift variation in one patient. Interestingly, two of these missense variants were previously reported in an autosomal recessive pattern of inheritance and here are associated with a dominant effect.ConclusionsClinicoradiologic characteristics of heterozygous HTRA1‐related CSVD may overlap with sporadic CSVD. Heterozygous HTRA1 variants can contribute to dominant or recessive disease mechanisms.
Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population
Rattan, Puru , Penrice, Daniel D. , Ahn, Joseph , Ferrer, Alejandro, Patnaik, Mrinal M. , Shah, Vijay H. , Kamath, Patrick S. , Mangaonkar, Abhishek A. , Simonetto, Douglas A. , Ahn, Joseph C , Penrice, Daniel , Simonetto, Douglas A , Ferrer, Alejandro

Mayo Clinic

Hepatology Communications | August 28, 2021 | Volume: 6 | Issue: 2 | Pages: 399-410

10.1002/hep4.1803 | PMID 34558851 Get It

Physiologic aging leads to attrition of telomeres and replicative senescence. An acceleration of this process has been hypothesized in the progression of chronic liver disease. We sought to examine the association of telomere length (TL) with liver disease and its impact on mortality risk. A cohort of 7,072 adults with leukocyte TL measurements from the National Health and Nutrition Examination Survey 1999‐2002 with mortality follow‐up through 2015 was analyzed. Liver disease was defined by aminotransferase levels and classified into etiology‐based and advanced fibrosis categories. Multivariable‐adjusted linear regression models estimated effect sizes, with 95% confidence intervals (CIs), of the presence of liver disease on TL. Cox regression models evaluated associations between TL and all‐cause mortality risk using adjusted hazard ratios (HRs). The cohort was representative of the US population with mean age 46.1 years and mean TL 5.79 kilobase pairs. No overall association between TL and liver disease was found; however, there was a significant negative association of TL and advanced liver fibrosis in individuals aged 65 and above. The liver disease cohort (HR 1.22, 95% CI 0.99‐1.51) and those with metabolic syndrome (HR 1.26, 95% CI 0.96‐1.67) had increased mortality risk with shorter TL. The relationship between TL and all‐cause mortality was stronger in women (HR 1.51, 95% CI 1.02‐2.23) and in non‐Hispanic Whites (HR 1.37, 95% CI 1.02‐1.84). Conclusion: Shortened leukocyte TL is independently associated with advanced liver disease at older ages, and with a higher risk of all‐cause mortality in those with liver disease. These associations reaffirm the need to better understand the role of telomeres in the progression of liver disease.